Impaired Cognition without Behavioral Problems in Pediatric Clinically Isolated Syndrome (CIS) (P02.113)

• DOI: 10.1212/wnl.80.7_supplement.p02.113
• Publication Date: 2023-12-07T03:09:48Z
• Authors: Lauren Krupp; Leigh Charvet; Dana Serafin; Laura Julian; Joseph Ackerson; Ralph Benedict; Ellen Braaten; Tanya Brown; Ellen O'Donnell; Joy Parrish; Thomas Preston; Michael Zaccariello; Anita Belman; Tanuja Chitnis; Mark Gorman; Emma Kaufman; Jayne Ness; Marc Patterson; Moses Rodriguez; Emmanuelle Waubant; Bianca Weinstock-...; Ann Yeh

OBJECTIVE: To characterize cognitive and behavioral functioning in children younger than 18 years of age with clinically isolated syndrome (CIS). BACKGROUND: Cognitive impairment is estimated to occur one third MS, but its frequency at the time first clinical event i.e. CIS, unknown. As occurs adults this disease stage, we hypothesized that impairments would also be identified pediatric CIS. DESIGN/METHODS: We evaluated 44 enrolled from six MS centers across USA. Participants completed a test battery participants parents Behavior Assessment System for Children, Second Edition (BASC-2) as measure psychological distress. defined poor performance (one standard deviation (SD) or more below published normative values) on ≥ 1/3 measures. RESULTS: At testing, had mean 14.8± 2.6 , symptom duration 0.8±1.7 years, median Expanded Disability Status Scale (EDSS) 1.3 (0 6.5). A total 8 (18%) CIS met criteria impairment. Poor was most frequently found visuomotor integration (57%) speeded information processing (34%). Elevated symptoms distress were commonly reported parent ratings depression (n=5, 11%), anxiety (n=4, 9%) somatization 9%). The number scales (parent self) rated significant range not associated performances 1 SD norms (r=.02, p>.94), EDSS (r=.20, p>.43), presence overall sample who classified higher scores (p CONCLUSIONS: detectable patient- parent-reported Supported by: National Multiple Sclerosis Society. Disclosure: Dr. Krupp has received personal compensation activities Teva Neuroscience, Biogen Idec, EMD Serono, MEDA Corp, Acorda Therapeutics, Betaseron/Bayer Healthcare, Gerson Lehrman Group, Guidepoint Global, Adler, Cohen, Harvey Wakeman. royalty payments Genzyme, Zymogenetics, Ortho-McNeil, ER Squibb & Sons. research support Genentech, Celgene Corporation, Garnett McKeen Laboratory Incorporated, Institutes Health, Slomo Cindy Silvian Foundation, Foundation Lourie Foundation. Charvet nothing disclose. Serafin Julian Inc. an employee. Ackerson Benedict Actelion, Bayer, Novartis, MedImmune, Serono Neuroscience. Psychological Resources. Therapeutics Idec. Braaten Brown O9Donnell Parrish Preston Zaccariello Belman Chitnis Sanofi-Aventis Pharmaceuticals, EMD-Serono, Merck Serono. Gorman receievd Shire HGT, Orphazyme, Stem cells, Inc, Amicus. NIH Actelion. Kaufman Ness Patterson Rodriguez Waubant Roche Diagnostics Neuroscience consultant, advisory board member and/or speaker. Idec Sanofi-Aventis. Weinstock-Guttman Inc., Pfizer, speaker participant board. Society, ITN, Aspreva-Roche, Cognition, Pharmaceuticals Group Novartis. Yeh